Elanco's Befrena™ has received USDA approval for treating canine allergic and atopic dermatitis, offering long-lasting relief for dogs while enhancing veterinary care.

Elanco (NYSE: ELAN) received USDA approval for Befrena (tirnovetmab), an anti‑IL31 monoclonal antibody injection for canine allergic and atopic dermatitis, recommended at a 6–8 week dosing interval. Befrena is approved for dogs of any age and is expected to launch in the first half of 2026. This marks Elanco's second dermatology approval in under 18 months and positions the product in the estimated $1.3 billion U.S. canine dermatology market. The approval complements Elanco's Zenrelia oral JAK inhibitor franchise; Zenrelia's label retains a boxed warning advising discontinuation for 28 days to 3 months around vaccination.

Elanco's second dermatology product approval in less than 18 months in the estimated $1.3 billion U.S. canine dermatology market Befrena has been shown to be effective for treatment of dogs of any age against canine atopic dermatitis and allergic dermatitis for 6 to 8 weeks of treatment,...

Elanco has successfully completed a major expansion of its Kansas manufacturing facility, enhancing its production of innovative monoclonal antibody treatments for pets.

Elanco wins USDA approval for Befrena to treat canine dermatitis. Find out how this boosts its antibody strategy and reshapes competition in pet health.

Reported Monday, May 18 - 7:29am EDT (TheFly subscription required to read more.)

Reported Wednesday, Dec 31 - 2:02pm EST (TheFly subscription required to read more.)

Elanco's Befrena™ offers a breakthrough solution for canine allergic dermatitis. This new monoclonal antibody promises rapid itch relief and improved treatment duration, redefining pet dermatology.

In its recent report, Elanco Animal Health detailed strong financial results for Q4 and full year 2025, driven by innovation and growth, along with ambitious targets for 2026.

Elanco (NYSE: ELAN) launched Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody injection for canine allergic and atopic dermatitis in the $1.3 billion U.S. canine dermatology market. The phased U.S. launch begins via an Early Experience Program.Befrena starts controlling itch within 24 hours, provides 6–8 weeks relief, has no age or weight restrictions, and is administered as an in-clinic injection. Approved by the USDA in December 2025, Befrena makes Elanco the only pet health company with two USDA-approved mAb products.

Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight...